
|Articles|May 1, 2004
Intravitreal triamcinolone may be helpful PDT adjunct for AMD
Fort Lauderdale, FL-Intravitreal triamcinolone may enhance the efficacy of photodynamic therapy (PDT) with verteporfin (Visudyne, QLT Phototherapeutics/Novartis Ophthalmics) and decrease the number of re-treatments for eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), according to the preliminary results of an open-label study presented by Daniel B. Roth, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
Eye exams could enable earlier detection of systemic disease
4
FDA approves NDA labeling supplement allowing re-administration of iDose TR
5



























